UC Davis CCC receives first SPORE grant for immunotherapy in head and neck cancer

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

Washington University researchers at Siteman Cancer Center received a $10.8 million grant throughNCI’s Specialized Programs of Research Excellence. Led by principal investigator Daniel C. Link, the five-year grant is a renewal of a previous SPORE grant in leukemia.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Breast cancer-causing gene predisposes Black women to TNBC

UC Davis Comprehensive Cancer Center researcher Sanchita Bhatnagar and her team have been working to get to the bottom of the genetic determinants of the racial disparity in triple-negative breast cancer.

January 17, 2025

Vol.51 No.02

In Brief

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.

November 15, 2024

Vol.50 No.43

In Brief

Longevity Consortium receives $45M grant

The Longevity Consortium received a five-year, $45 million grant to move the consortium’s work to its next stage: integrating results from numerous studies about the factors that contribute to longer and healthier lives.

November 01, 2024

Vol.50 No.41

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

October 18, 2024

Vol.50 No.39

By Jacquelyn Cobb

UC Davis CCC receives first SPORE grant for immunotherapy in head and neck cancer

YOU MAY BE INTERESTED IN

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

Breast cancer-causing gene predisposes Black women to TNBC

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

Longevity Consortium receives $45M grant

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

Renew today!

Subscriber content

Never miss an issue!

Login